Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fumiko Nakatsu
Institution:
Novartis (Japan)
Observed institutions:
Novartis (Japan),
Icahn School of Medicine at Mount Sinai
ORCID:
0000-0003-4290-7578
Observed ORCID:
0000-0003-4290-7578
OpenAlex ID:
A5111093888
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
·
Cancer Research
·
21
PDF
A greater reduction in γ-GTP was associated with achieving BP <140/90 mmHg without antihypertensive medication among individuals who newly developed Grade I hypertension
2026
·
Ryoichi Ohara
, Fumiko Nakatsu
, et al.
·
Journal of Cardiology
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Supplementary Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Supplementary Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
PDF
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
2023
·
Sunny Mai
, Alan Hodges
, et al.
Show more works
View as search
Works count:
16
Citation count:
21
H-index:
1
I10-index:
1
Year
Topic
Type